137 related articles for article (PubMed ID: 38261976)
1. Delaying Prostate-Specific Antigen Progression in Biochemically Recurrent Prostate Cancer: Is It Clinically Meaningful?
Childs DS; Orme JJ; Ravi P
J Clin Oncol; 2024 Apr; 42(10):1095-1097. PubMed ID: 38261976
[No Abstract] [Full Text] [Related]
2. Prostate Specific Antigen and Prostate Specific Antigen Doubling Time Predict Findings on
Markowski MC; Sedhom R; Fu W; Gray JCR; Eisenberger MA; Pomper MG; Pienta KJ; Gorin MA; Rowe SP
J Urol; 2020 Sep; 204(3):496-502. PubMed ID: 32250727
[TBL] [Abstract][Full Text] [Related]
3. Association between immunosuppressive cytokines and PSA progression in biochemically recurrent prostate cancer treated with intermittent hormonal therapy.
Hawley JE; Pan S; Figg WD; Lopez-Bujanda ZA; Strope JD; Aggen DH; Dallos MC; Lim EA; Stein MN; Hu J; Drake CG
Prostate; 2020 Mar; 80(4):336-344. PubMed ID: 31899823
[TBL] [Abstract][Full Text] [Related]
4. Fluorine-18-Labeled Fluciclovine PET/CT in Primary and Biochemical Recurrent Prostate Cancer Management.
Marcus C; Butler P; Bagrodia A; Cole S; Subramaniam RM
AJR Am J Roentgenol; 2020 Aug; 215(2):267-276. PubMed ID: 32551903
[No Abstract] [Full Text] [Related]
5. Itraconazole as a Noncastrating Treatment for Biochemically Recurrent Prostate Cancer: A Phase 2 Study.
Lee M; Hong H; Kim W; Zhang L; Friedlander TW; Fong L; Lin AM; Small EJ; Wei XX; Rodvelt TJ; Miralda B; Stocksdale B; Ryan CJ; Aggarwal R
Clin Genitourin Cancer; 2019 Feb; 17(1):e92-e96. PubMed ID: 30327180
[TBL] [Abstract][Full Text] [Related]
6. 18F-PSMA-1007 PET/CT Detects Micrometastases in a Patient With Biochemically Recurrent Prostate Cancer.
Giesel FL; Kesch C; Yun M; Cardinale J; Haberkorn U; Kopka K; Kratochwil C; Hadaschik BA
Clin Genitourin Cancer; 2017 Jun; 15(3):e497-e499. PubMed ID: 28131751
[No Abstract] [Full Text] [Related]
7. The use of
Raveenthiran S; Yaxley J; Gianduzzo T; Kua B; McEwan L; Wong D; Tsang G; MacKean J
Prostate Cancer Prostatic Dis; 2019 Sep; 22(3):385-390. PubMed ID: 31363165
[TBL] [Abstract][Full Text] [Related]
8. Management of biochemically recurrent prostate cancer: molecular imaging perspective.
Lorca AM
World J Urol; 2018 Feb; 36(2):321-322. PubMed ID: 29134278
[No Abstract] [Full Text] [Related]
9. Plasma carotenoids and tocopherols in relation to prostate-specific antigen (PSA) levels among men with biochemical recurrence of prostate cancer.
Antwi SO; Steck SE; Zhang H; Stumm L; Zhang J; Hurley TG; Hebert JR
Cancer Epidemiol; 2015 Oct; 39(5):752-62. PubMed ID: 26165176
[TBL] [Abstract][Full Text] [Related]
10.
Mena E; Lindenberg ML; Turkbey IB; Shih JH; Harmon SA; Lim I; Lin F; Adler S; Eclarinal P; McKinney YL; Citrin D; Dahut W; Wood BJ; Krishnasamy V; Chang R; Levy E; Merino M; Pinto P; Eary JF; Choyke PL
J Nucl Med; 2020 Jun; 61(6):881-889. PubMed ID: 31676732
[TBL] [Abstract][Full Text] [Related]
11. Management of biochemically recurrent prostate cancer following local therapy.
Kolodziej M
Am J Manag Care; 2014 Dec; 20(12 Suppl):S273-81. PubMed ID: 25734963
[TBL] [Abstract][Full Text] [Related]
12.
Garg I; Nathan MA; Packard AT; Kwon ED; Larson NB; Lowe V; Davis BJ; Haloi R; Mahon ML; Goenka AH
J Cancer Res Ther; 2021; 17(2):358-365. PubMed ID: 33063697
[TBL] [Abstract][Full Text] [Related]
13. Abiraterone acetate plus prednisone in non-metastatic biochemically recurrent castration-naïve prostate cancer.
Spetsieris N; Boukovala M; Alafis I; Davis J; Zurita A; Wang X; Tu SM; Chapin BF; Aparicio A; Corn P; Wang J; Subudhi SK; Araujo J; Papadopoulos J; Pruitt L; Weldon JA; Logothetis CJ; Efstathiou E
Eur J Cancer; 2021 Nov; 157():259-267. PubMed ID: 34536949
[TBL] [Abstract][Full Text] [Related]
14. Re: Acute Toxicity and Quality of Life After Dose-intensified Salvage Radiation Therapy for Biochemically Recurrent Prostate Cancer After Prostatectomy: First Results of the Randomized Trial SAKK 09/10.
Dell'Oglio P; Suardi N
Eur Urol; 2016 May; 69(5):966. PubMed ID: 27301993
[No Abstract] [Full Text] [Related]
15. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes.
Cookson MS; Aus G; Burnett AL; Canby-Hagino ED; D'Amico AV; Dmochowski RR; Eton DT; Forman JD; Goldenberg SL; Hernandez J; Higano CS; Kraus SR; Moul JW; Tangen C; Thrasher JB; Thompson I
J Urol; 2007 Feb; 177(2):540-5. PubMed ID: 17222629
[TBL] [Abstract][Full Text] [Related]
16. Pilot Comparison of ⁶⁸Ga-RM2 PET and ⁶⁸Ga-PSMA-11 PET in Patients with Biochemically Recurrent Prostate Cancer.
Minamimoto R; Hancock S; Schneider B; Chin FT; Jamali M; Loening A; Vasanawala S; Gambhir SS; Iagaru A
J Nucl Med; 2016 Apr; 57(4):557-62. PubMed ID: 26659347
[TBL] [Abstract][Full Text] [Related]
17. [Treatment option for locally and/or biochemically radiorecurrent prostate cancer].
Okihara K
Nihon Rinsho; 2011 Jun; 69 Suppl 5():431-4. PubMed ID: 22208017
[No Abstract] [Full Text] [Related]
18. Interpreting Testosterone and Concomitant Prostate Specific Antigen Values during Androgen Deprivation Therapy for Recurrent Prostate Cancer.
Tremblay S; Summers-Trasiewicz L; Pouliot F; Crook JM; Ding K; Klotz L; Toren P
J Urol; 2021 Nov; 206(5):1166-1176. PubMed ID: 34184929
[TBL] [Abstract][Full Text] [Related]
19. Lenalidomide modulates IL-8 and anti-prostate antibody levels in men with biochemically recurrent prostate cancer.
Zabransky DJ; Smith HA; Thoburn CJ; Zahurak M; Keizman D; Carducci M; Eisenberger MA; McNeel DG; Drake CG; Antonarakis ES
Prostate; 2012 Apr; 72(5):487-98. PubMed ID: 21748755
[TBL] [Abstract][Full Text] [Related]
20. Antigen-presenting cells 8015 (Provenge) in patients with androgen-dependent, biochemically relapsed prostate cancer.
Beinart G; Rini BI; Weinberg V; Small EJ
Clin Prostate Cancer; 2005 Jun; 4(1):55-60. PubMed ID: 15992463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
